Objective To study the effects and mechanisms of major immune nutrients and to introduce the progresses of clinical applications about enteral immunonutrition. Methods The related literatures about the effects and clinical applications of enteral immunonutrition were reviewed. Results Infection rate can be reduced and the hospitalization can be shortened as a result of the improved nutritional status and immune competence of patients which can be enhanced by reasonable enteral immune nutrition. Most of the patients suffering from serious diseases can benefit from enteral immunonutrition, such as gastrointestinal cancers, post-transplantation complications, chronic liver disorders, acute pancreatitis and so on. However, as a new nutrition therapy, the clinical use of enteral immunonutrition in critically ill patients is still controversial. Conclusions Enteral immunonutrition plays an important role in the nutritional support of patients with serious diseases, such as gastrointestinal cancers, organ failures. However, much work remains to be done.
Objective To evaluate the effectiveness of enteral immunonutrition for patients with acute pancreatitis. Methods The randomized controlled trials (RCTs) about enteral immunonutrition for patients with acute pancreatitis were searched in following databases: PubMed (1966 to August 2012), MEDLINE (Ovid, 1946 to August 2012), CENTRAL (Issue 3, 2012), CBM (1978 to August 2012), CNKI (1979 August 2012), VIP (1989 to August 2012), and WanFang Data (1977 to August 2012). The relevant materials and each reference of literature were also searched manually. Two reviewers independently screened the literature according to the predefined inclusion and exclusion criteria, extracted the data and assessed the quality, and then the meta-analysis was conducted by using RevMan 5.0 software. Results A total of 6 RCTs involving 197 patients were included. The results of meta-analysis showed that there were no significant differences between the enteral immunonutrition group and the routine enteral nutrition group in following aspects: infectious complications and mortality rate, length of stay, level of C-reactive protein and numeration of leucocyte after treatment, and APACHE II score. Conclusion At present, no evidence shows enteral immunutrition is superior to routine enteral nutrition in acute pancreatitis. For the quantity and quality limitation of the included studies, more high-quality and large-sample RCTs are required to investigate the proper ingredients and dosage of enteral immunonutrition suitable for patients with acute pancreatitis.
ObjectiveTo evaluate whether three preoperative nutritional scoring indices, the Naples prognostic score (NPS), controlling nutritional status (CONUT), and prognostic nutritional index (PNI), are associated with the clinicopathological characteristics and prognosis of patients with esophageal squamous cell carcinoma (ESCC). MethodsA retrospective analysis was conducted on clinical data from ESCC patients who underwent surgical treatment in the Department of Thoracic Surgery at the First Hospital Affiliated to the University of Science and Technology of China between 2017 and 2019. Based on NPS, CONUT, and PNI scores, optimal cutoff values were determined using X-tile software to divide patients into a high-value group and a low-value group. Differences in clinicopathological characteristics between groups were compared. Survival analysis was performed using Kaplan-Meier method and log-rank test. Multivariate Cox proportional hazards model was used to analyze factors influencing overall survival (OS). The predictive performance of each nutritional index was evaluated by area under receiver operating characteristic curve (AUC). Differences in AUC values among ROC curves were compared using MedCalc software. ResultsA total of 606 ESCC patients were included, comprising 459 males and 147 females, with a mean age of (65.98±7.60) years. Univariate analysis showed that age, squamous cell carcinoma antigen level, NPS, CONUT, PNI, TNM stage, degree of differentiation, and tumor size were all risk factors affecting OS in ESCC patients (P<0.05). Multivariate analysis revealed that age, TNM stage, and NPS were independent risk factors for OS. Among the indices analyzed for prognostic efficacy via AUC values comparison, NPS demonstrated the highest AUC value (0.681) with statistically significant superiority over PNI and CONUT (P<0.05). Conclusion Age, TNM stage, and NPS are independent risk factors affecting the OS of ESCC patients after surgery. Moreover, prognostic evaluation efficacy of NPS surpasses that of PNI and CONUT, indicating its potential as a significant indicator for predicting outcomes in ESCC patients.
ObjectiveTo study the clinical application of enteral microecopharmaceutics immunonutrition in the peroperation of colorectal cancer. MethodsLiteratures about enteral microecopharmaceutics immunonutrition published in China and abroad were collected and reviewed. ResultsEarly clinical application of enteral microecopharmaceutics immunonutrition in the perioperation can greatly improve the nutritional status of patients with colorectal cancer, increase the patients' immune function, reconstruct the intestinal flora, and reduce the incidence of complications. ConclusionsThe clinical application of enteral microecopharmaceutics immunonutrition in the perioperation of colorectal cancer can obviously improve patients' nutritional status and immune function, reduce the stress response, and improve its prognosis, but the use of best dose still need further study.
Objective To systematically review the effects of enteral immunonutrition (EIN) on postoperative infection and the length of hospital stay in patients with gastrointestinal cancer after surgery, in order to provide high quality evidence for the rational perioperation nutrition plan for patients with malignant gastrointestinal tumor. Methods Randomized controlled trials (RCTs) published in English about application of EIN vs. general treatment for gastrointestinal surgery published from Jan. 1st, 1997 to Oct. 31st 2012 were retrieved in the following databases: PubMed, Ovid, and EMbase. References of the included studies were also retrieved. According to the inclusion and exclusion criteria, two reviewers independently screened studies, extracted data, and evaluated the methodological quality. Then, meta-analysis was conducted using RevMan 5.2 software. Results 19 RCTs involving 2 298 patients were included. The results of meta-analysis showed that: there was no significant difference between the postoperative EIN group and the control group in reducing the risk of postoperative infection (OR=0.91, 95%CI 0.56 to 1.47, P=0.70); But postoperative and perioperative EIN had reduced the risk of postoperative infection with a significant difference (OR=0.57, 95%CI 0.39 to 0.82, P=0.002; OR=0.52, 95%CI 0.35 to 0.76, P=0.000 9). Additionally, the results of sensitivity analysis revealed that: no matter when EIN was used (during preoperative, postoperative, or perioperative periods), it reduced the length of postoperative hospital stay with significant differences, compared to the standard nutrition group (OR= ?2.39, 95%CI ?3.28 to ?1.49, Plt;0.000 01; OR= ?2.42, 95%CI ?4.07 to ?0.78, P=0.004; OR= ?2.76, 95%CI ?3.46 to ?2.06, Plt;0.000 01). Conclusion Current evidence shows that perioperative EIN can decrease postoperative infection and reduce the length of hospital stay of patients with malignant gastrointestinal tumor. Due to the limited quantity and quality of the included studies, high quality RCTs are needed to verify the above conclusion.